Imatinib mesylate treatment for platelet-derived growth factor receptor alfa-positive choroid plexus carcinoma

  • Chihiro Kawakami | ped076@poh.osaka-med.ac.jp Department of Pediatrics, Osaka Medical College, Takatsuki, Osaka, Japan.
  • Akiko Inoue Department of Pediatrics, Osaka Medical College, Takatsuki, Osaka, Japan.
  • Kimitaka Takitani Department of Pediatrics, Osaka Medical College, Takatsuki, Osaka, Japan.
  • Motomu Tsuji Department of Pathology, Osaka Medical College, Takatsuki, Osaka, Japan.
  • Kimiko Wakai Department of Laboratory Medicine, Gunnma Childrens’ Medical Center, Shibukawa, Gunnma, Japan.
  • Hiroshi Tamai Department of Pediatrics, Osaka Medical College, Takatsuki, Osaka, Japan.

Abstract

We herein report a female child with choroid plexus carcinoma treated with standard dose of imatinib at disease recurrence. This patient failed initial twice-surgical resections, central nervous system (CNS) irradiation, and adjuvant chemotherapies and high-dose thiotepa and melphalan with auto peripheral blood stem cell rescue. Finally, imatinib treatment was undergone as a palliative setting, however the tumor did not reduce and the patient died of tumor bleedings. We consider that the reasons for the failure are as follows: i) adequate CNS level of imatinib were not obtained because of the blood brain barrier, ii) the lack of plateletderived growth factor receptor beta expression in our case may have a crucial role.

Downloads

Download data is not yet available.

Author Biography

Chihiro Kawakami, Department of Pediatrics, Osaka Medical College, Takatsuki, Osaka

MD

 

Published
2012-05-07
Section
Case Reports
Keywords:
imatinib mesylate, platelet derived growth factor receptor (PDGFR) alfa, choroid plexus carcinoma.
Statistics
Abstract views: 567

PDF: 366
HTML: 154
Share it

PlumX Metrics

PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

How to Cite
Kawakami, C., Inoue, A., Takitani, K., Tsuji, M., Wakai, K., & Tamai, H. (2012). Imatinib mesylate treatment for platelet-derived growth factor receptor alfa-positive choroid plexus carcinoma. Clinics and Practice, 2(2), e49. https://doi.org/10.4081/cp.2012.e49